Revance Therapeutics, Inc. (RVNC) Stock: A Strong Pick In The Biotechnology Space?

0

Revance Therapeutics, Inc. (RVNC) is headed up in the market today. The stock, focused in the biotechnology space, is presently trading at $13.08 after climbing 7.04% so far in today’s session. When it comes to biotech stocks, there are quite a few factors that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines relating to RVNC:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-07-19 10:30PM Edited Transcript of RVNC earnings conference call or presentation 5-Aug-19 8:30pm GMT
Aug-06-19 08:24PM Revance Therapeutics (RVNC) Q2 2019 Earnings Call Transcript
Aug-05-19 04:05PM Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update
02:30PM Revance Therapeutics, Inc. to Host Earnings Call
Jul-29-19 04:05PM Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019

However, any time investors are making an investing decision, prospective investors should look at far more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s going on with Revance Therapeutics, Inc..

Recent Movement Out of RVNC

Although a single session gain, like the move that we’re seeing from Revance Therapeutics, Inc. may make some investors jump for joy, a single session gain alone should not be the reason for a decision to, or not to, invest in a company. It is generally smart to take a look at trends for a period longer than a single trading day. When it comes to RVNC, below are the returns that we’ve seen:

  • Past Seven Days – In the last week, RVNC has seen a change in price amounting to 4.14%.
  • Monthly – The return on investment from Revance Therapeutics, Inc. over the past month comes to 5.91%.
  • Past Three Months – In the past three months, the company has generated a return of 2.03%
  • Past Six Months – In the previous 6 months, we have seen a change that amounts to -22.88% from the stock.
  • Year To Date – Since the open of this year RVNC has resulted in a ROI of -35.02%.
  • Full Year – Lastly, in the last full year, we have seen a change that works out to -51.56% from RVNC. Over this period, the stock has traded at a high price of -52.95% and a low price of 26.13%.

Rations That You Should Consider

Digging into various key ratios associated with a stock can give prospective investors a view of how risky and/or potentially profitable a an investment option might be. Here are a few of the key ratios to look at when digging into RVNC.

Short Ratio – The short ratio is a tool that’s used to measure the level of short interest. As the ratio heads up, it shows that more investors are expecting that the stock is going to fall. Across the sector, biotechnology stocks can carry a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the space. Nonetheless, with regard to Revance Therapeutics, Inc., the stock’s short ratio is 12.17.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure the company’s abilities to cover its debts when they come due based on quick assets or current assets. In the biotechnology industry, several companies are heavily reliant on the continuation of support from investors, the current and quick ratios can be bad. However, several good picks in the biotech industry do have great quick and current ratios. In terms of RVNC, the quick and current ratios come to 8.10 and 8.10 respectively.  

Book To Share Value – The book to share value compares the book value of assets owned by the company to the share price. In this case, that ratio works out to 5.32.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many early stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotech stock, this is a very important ratio to think about. In this case, the cash to share value is 6.02.

What Analysts Say About Revance Therapeutics, Inc.

While it’s never a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their analysis when validating your own opinions when it comes to making investment decisions in the biotech sector. Here are the most recent moves that we have seen from analysts when it comes to RVNC.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-11-19 Initiated Barclays Overweight $28
Feb-15-19 Initiated Wells Fargo Market Perform
Feb-14-19 Initiated H.C. Wainwright Buy $25
Jan-29-19 Initiated Stifel Buy $50
Nov-16-18 Upgrade Guggenheim Neutral → Buy

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in RVNC, here’s what we’re seeing:

Institutions own 85.34% of the company. Institutional interest has moved by 0.28% over the past three months. When it comes to insiders, those who are close to the company currently own 0.90% percent of RVNC shares. Institutions have seen ownership changes of an accumulative -4.15% over the last three months.

Interested In How Many Shares Are Available?

Traders seem to like to know the counts of shares both outstanding and available. In terms of Revance Therapeutics, Inc., there are currently 45.04M and there is a float of 41.99M. These data mean that of the total of 45.04M shares of RVNC currently in existence today, 41.99M are able to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to RVNC, the short percent of the float is 12.42%.

Financial Results And Expectations

What have ween seen from RVNC in terms of financial results?Here’s the information:

  • Analyst Expectations – At the moment, Wall Street analysts are expecting that RVNC will come up with earnings per diluted share in the amount of -3.72, with -0.91 to be reported in the report for the current quarter. Although this is not associated with earnings, because we’re chatting on the topic of analysts, the stock is presently rated a 1.90 on a scale from 1 to 5 on which 1 is the worst possible analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the past half decade, Revance Therapeutics, Inc. has reported a movement in sales that adds up to 43.30%. Earnings per diluted share over the period have experienced movement in the amount of 1.30%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is often represented in the world of humans, RVNC has created a change in earnings that amounts to 12.90%. The company has also seen movement with regard to sales volume that adds up to 50.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was developed by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here